Inhalon Biopharma is a fledgling immunotherapy firm that is working on an inhaled antibody platform to treat various acute respiratory infections. The company's intellectual property encompasses several authorized U.S. and EU patents that broadly encompass the structure and application of aerosolized antibodies, which have been licensed from The University of North Carolina at Chapel Hill and Johns Hopkins University. It has garnered support from prominent angel investors in the life science sector such as Life Science Angels, Band of Angels, Sand Hill Angels, Breakout Labs, as well as individual investors. Inhalon has also been granted a contract by the U.S. Army Medical Research and Development Command to carry out research.